Published in

Karger Publishers, Kidney and Blood Pressure Research, 10(47), p. 605-615, 2022

DOI: 10.1159/000526909

Links

Tools

Export citation

Search in Google Scholar

Characteristics and Survival Results of Peritoneal Dialysis Patients Suffering from COVID-19 in Turkey: A Multicenter National Study

This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

<b><i>Introduction:</i></b> We aimed to study the characteristics of peritoneal dialysis (PD) patients with coronavirus disease-19 (COVID-19), determine the short-term mortality and other medical complications, and delineate the factors associated with COVID-19 outcome. <b><i>Methods:</i></b> In this multicenter national study, we included PD patients with confirmed COVID-19 from 27 centers. The baseline demographic, clinical, laboratory, and radiological data and outcomes at the end of the first month were recorded. <b><i>Results:</i></b> We enrolled 142 COVID-19 patients (median age: 52 years). 58.2% of patients had mild disease at diagnosis. Lung involvement was detected in 60.8% of patients. Eighty-three (58.4%) patients were hospitalized, 31 (21.8%) patients were admitted to intensive care unit and 24 needed mechanical ventilation. Fifteen (10.5%) patients were switched to hemodialysis and hemodiafiltration was performed for four (2.8%) patients. Persisting pulmonary symptoms (<i>n</i> = 27), lower respiratory system infection (<i>n</i> = 12), rehospitalization for any reason (<i>n</i> = 24), malnutrition (<i>n</i> = 6), hypervolemia (<i>n</i> = 13), peritonitis (<i>n</i> = 7), ultrafiltration failure (<i>n</i> = 7), and in PD modality change (<i>n</i> = 8) were reported in survivors. Twenty-six patients (18.31%) died in the first month of diagnosis. The non-survivor group was older, comorbidities were more prevalent. Fever, dyspnea, cough, serious-vital disease at presentation, bilateral pulmonary involvement, and pleural effusion were more frequent among non-survivors. Age (OR: 1.102; 95% CI: 1.032–1.117; <i>p</i>: 0.004), moderate-severe clinical disease at presentation (OR: 26.825; 95% CI: 4.578–157.172; <i>p</i> &#x3c; 0.001), and baseline CRP (OR: 1.008; 95% CI; 1,000–1.016; <i>p</i>: 0.040) were associated with first-month mortality in multivariate analysis. <b><i>Discussion/Conclusions:</i></b> Early mortality rate and medical complications are quite high in PD patients with COVID-19. Age, clinical severity of COVID-19, and baseline CRP level are the independent parameters associated with mortality.